Member Info for inanaco

sorry you have lost me Crumbs ..

Did the major investors in Scancell sell out at 50p .. ? when the SP was 50p ?

Ivy worked for Merck .. what has that got to do with BioNtech's private status ?

Ivy is a salesman ... not a director of Merck

Crumbs really ....

""""" can do it without resorting to the needs of SH as there are none.
Hope this makes sense """""

he said the Private company has no shareholders ...

so exactly what do you think it means ?

the Family business in this case is an investment vehicle .. its not as maybe Ivy imagines a God Father Figure sitting on the Board

Strüngmann Family Office

that would imply the Strüngmann are sole traders .... and own 100% of BioNtech

need = did

no idea mate ...

not sure what credentials an anonymous person has

hey ... if you love Val buy the share

its only IMHO ...

however i need give you all these warnings at 7p ... and 4p ... and 1p

i also disagreed with Yoda and Multibagger big time ... about the quick and speedy trial 4 years ago .. which is still going

anyway i have history of telling this BB that the science is not that great ... ATB

yes but they are only validating what Val present by printing ... what they are not doing is checking to see if what is presented is actual Fact ... as to do that, they would have to re run the trial to validate it ...
because the data is still "circumstantial " its open to all sorts of interpretation

so i would rank a peer review by an anonymous source as little value

on what basis ?

palliative care or a treatment for lung cancer ?

until you have a full blown trial that actually is completed ... ie not stopped at 7 patients instead of the 20 planned

with a proper control arm ... not one "created" ... (which means the "creator" has influence in what is submitted)

the trial as i see it contains no useful info that anyone could actually value ... because N7 ie number of patients is worthless to statistics considering the gains are potentially only "weeks"

if the gain was years ie .. late stage treated with 401 added years ... then N7 would have value

seconded ..

I said Val 401 ... Gilders01

Val 201 might be the game changer, but i will reserve judgement until they have treated at least 30 patients at the new Higher dose for about a year so lets see what happens end of 2019

But if they pull the plug and close the trial with the 6 patients at the higher dose after only 12 weeks ... questions should be asked

Think we have all shared the frustration of any small bio like SCLP not having the resources to develop their science as quickly as we would have liked

Please advise me when Scancell cash raising failed ? unable to fund its intended plans

Do you think you can just Hire more Lindy Durrants ? pop down the job centre ?

so yet again ... Comosnybthey questions my intellect .. really ?

basically i will translate what you have written

because a private company floats onto a stock market it loses flexibility and becomes to structured ...

so why would they do it ?

1/ ability to raise equity on the stock market
2/ gives Shareholders the chance to trade shares
3/ Raises capital on the IPO
4/ Provides a regulatory system that is transparent.
5/ Increases flexibility because it allows the options above

If the capitalist system did not think it would work, we would not have stock markets

Comosnybthey

Comosnybthey can do it without resorting to the needs of SH as there are none.
Hope this makes sense

private companies have shareholders .... without them who owns the company ?

should have added BioNtech ........ it's a Private company as such the Share Price cannot be evaluated by any market

as usual makes no sense at all ...

peer approved ?

which Peer has approved VAL 401 ...Lord Adonis ?

well all plain sailing then ...... the share price has not fallen ....over the past year and the number of shares did not increase by a factor of 5 ...

all based on the fact that 201 ... is part of a billion dollar market and 401 will be sold or licensed in a few weeks

side bet .......... nothing will come of it in the next 3 months ... or ever,

as a serious investor in Bio with a pretty good understanding of trial data, what has been presented with 401 is the worst data fudge ever ....

I now cannot work out if its an end of life happy pill ... or a placebo cancer tablet that makes you happy while on morphine because of its antipsychotic properties

Uncanny ... what actually does it do ? as the trial was fudged with a fake control arm

why do we spend so much time on our epitopes ?

Epitope maps support IP
Shotgun mutagenesis epitope mapping of antibodies against HER2 revealed a novel epitope (orange spheres). Epitope maps provide supporting data for intellectual property (patent) claims.
Epitope mapping has become prevalent in protecting the intellectual property (IP) of therapeutic mAbs. Knowledge of the specific binding sites of antibodies strengthens patents and regulatory submissions by distinguishing between current and prior art (existing) antibodies.[8][9][20] The ability to differentiate between antibodies is particularly important when patenting antibodies against well-validated therapeutic targets (e.g., PD1 and CD20) that can be drugged by multiple competing antibodies.[21] In addition to verifying antibody patentability, epitope mapping data have been used to support broad antibody claims submitted to the United States Patent and Trademark Office.[9][10]

Epitope data have been central to several high-profile legal cases involving disputes over the specific protein regions targeted by therapeutic antibodies.[20] In this regard, the Amgen v. Sanofi/Regeneron PCSK9 inhibitor case hinged on the ability to show that both the Amgen and Sanofi/Regeneron therapeutic antibodies bound to overlapping amino acids on the surface of PCSK9.[22]

Because we have to protect them ....................

explained this before ..........

TCR searching out individual cancer patients TCR when 95% of the patients have patient specific Neo Antigens is an enormous task ...

Using the same TCR technique with patients that all have varying degrees of Neo Antigens that are Homocitrullinated or cittrulinated narrows the target range to a few ...

the cost saving implications to BioNtech is huge if it switches to the "Known" modi 1/2 epitopes

this is why BioNtech sees the future with Scancell as it is the ONLY company in the World to have a suite of Antigens to every cancer under PATENT

Its a NO brainer if you appreciate how difficult it is to Find therapeutic Epitopes ...

It does not matter how great your vaccine design is, if you don't have a target epitope

which is why i keep highlighting the value of Immunobody .. as it seems the only vaccine to get the best out of TPR2 and GP100 ... considering these epitopes are NOT exclusive

and now we have two Brilliant Vaccines

Immunobody can use others epitopes ie TPR2 going after CD8 t cells

and Scancells own epitopes used with ISA Amplivant to form a potent peptide vaccine against Cd4+ t cells

the Value of moditope is off the charts because it does not need PD1 in late stage